Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dawn Biopharma
BioCentury | Mar 5, 2025
Emerging Company Profile
Bambusa: Combining validated I&I targets in bispecifics to broaden efficacy
With $105M in venture funding, Bambusa has moved quickly towards the clinic with bispecifics in-licensed from antibody powerhouse Biotheus
BioCentury | Feb 20, 2025
Finance
Bambusa’s $90M series A; Recursion-backed accelerator’s ‘pre-seed’ fund: Venture Report
Plus fundings around the globe for Eg 427, Atrandi and Reverb
BioCentury | Dec 5, 2024
Finance
Broadening Versant’s obesity portfolio, Antag plots clinical path with €80M
Also in BioCentury’s weekly Venture Report: Formela stepping back from Atlas’ new fund, nine-digit rounds for Nuvig and Maze, and more
BioCentury | Sep 24, 2024
Management Tracks
BMS alum Catherine Owen Adams to lead Acadia
Plus: René van der Merwe named CMO of Bambusa, and updates from ModeX and ChromaDex
BioCentury | Sep 12, 2024
Finance
Venture Report: Big rounds for Candid, Superluminal, PanTera
Plus: Rounds for Radiant, Vironexis, Bambusa, OrsoBio and F2G
BioCentury | Jun 11, 2024
Emerging Company Profile
Adcytherix: Emergence team reunites for another ADC company
French biotech to pursue novel targets with ADCs incorporating new and old payloads
BioCentury | May 30, 2024
Finance
Venture Report: Canadian VC Amplitude closes new fund; CinRx’s series C
Plus: Adcendo’s series A is again Denmark’s largest; VCs and foundations back Lucy
BioCentury | Oct 12, 2023
Politics, Policy & Law
Oct. 11 Quick Takes: European Parliament proposes amendments to pharma legislation
Plus: Early stop for Novo’s kidney outcomes study of semaglutide; Agomab raises $100M series B; and updates from MinervaX, FDA, ARPA-H, Tempest, Kanvas-Federation Bio
Items per page:
1 - 8 of 8